Drug intelligence / Profile preview

opv + bcg

Development stage
Unknown
Lead developer
Albert Sabin
Modality
Vaccines & Immunotherapeutics
Administration
Oral, Intradermal
01

Overview

OPV + BCG refers to the simultaneous administration of two live attenuated vaccines at birth or in early infancy: - Oral poliovirus vaccine (OPV), which contains live, attenuated polioviruses and is used to prevent poliomyelitis by inducing mucosal and systemic immunity against poliovirus. - Bacille Calmette-Guérin (BCG) vaccine, which contains a live, attenuated strain of Mycobacterium bovis and is used primarily for the prevention of severe forms of tuberculosis (TB), such as TB meningitis and miliary TB in children. Both vaccines are commonly administered together at birth in many countries with high prevalence of polio and tuberculosis. OPV works by stimulating an immune response against all three types of wild poliovirus (depending on formulation), while BCG induces cellular immunity that protects against severe TB. The combination is not a single product but rather co-administration according to national immunization schedules. Studies have shown that simultaneous administration may influence immune responses; for example, OPV given with BCG can reduce certain cytokine responses to purified protein derivative (PPD) from M. tuberculosis. Both vaccines are contraindicated in individuals with severe immunodeficiency due to risk of disseminated infection.

Other names
opv + bcg
02

Targets

TLR2 (Toll-like Receptor 2)TLR9 (Toll-like receptor 9)TLR4 (Toll-like receptor 4)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)

Beyond the preview

Go deeper on opv + bcg.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on opv + bcg.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call